Unique ID issued by UMIN | UMIN000047860 |
---|---|
Receipt number | R000054563 |
Scientific Title | A multicenter randomized controlled study to evaluate the effectiveness to share monitoring of daily symptoms between patients and physicians in the treatment of Parkinson's disease |
Date of disclosure of the study information | 2022/05/25 |
Last modified on | 2024/10/18 16:00:26 |
A multicenter randomized controlled study to evaluate the effectiveness to share monitoring of daily symptoms between patients and physicians in the treatment of Parkinson's disease
SHARE-PD
A multicenter randomized controlled study to evaluate the effectiveness to share monitoring of daily symptoms between patients and physicians in the treatment of Parkinson's disease
SHARE-PD
Japan |
Parkinson's Disease
Neurology |
Others
NO
The purpose of this research is to Verify how the data obtained from a wearable device, a smartphone and its application are used by physicians to affect the patient's condition and medical practice during the 6-month study period.
Others
Medical usefulness
MDS-UPDRS Total Score
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Active
2
Prevention
Other |
Using a wearable device, a smartphone and its application during the 6-month
Regular medical care
20 | years-old | <= |
Not applicable |
Male and Female
1. The participant has been diagnosed with Parkinson's disease on the basis of the International Parkinson and Movement Disorder Society (MDS) and has motor/non-motor symptoms that require clinically complex management.
2. The participant is capable of operating each device used in this study, and understanding and complying with protocol requirements, in the opinion of the investigator.
3. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
4. The participant is aged 20 years or older at the time of informed consent.
5. The participant is capable of visiting the outpatient clinic during the evaluation period.
1. The participant has metal allergy.
2. The participant has cognitive impairment that, in the opinion of the investigator, would interfere with the ability to report on symptoms and function.
3. The participant has unstable Parkinson's disease and comorbidities that would make outpatient visits difficult, in the opinion of the investigator.
4. The participant is judged by the investigator as being ineligible for any other reason.
110
1st name | Genko |
Middle name | |
Last name | Oyama |
Juntendo University Hospital
Department of Neurology
113-8431
3-1-3 Hongo, Bunkyo-ku, Tokyo
03-3813-3111
g_oyama@juntendo.ac.jp
1st name | Miwa |
Middle name | |
Last name | Izutsu |
Takeda Pharmaceutical Company Limited
Japan Medical Office
103-0023
1-1,Nihonbashi-Honcho 2-Chome,Chuo-ku,Tokyo
03-3278-2111
miwa.izutsu@takeda.com
Juntendo University Hospital
Takeda Pharmaceutical Company Limited
Profit organization
Research Ethics Committee Faculty of Medicine, Juntendo University
3 -1 -3 Hongo, Bunkyo-ku, Tokyo
03-5802-1584
hongo-rinri@juntendo.ac.jp
NO
2022 | Year | 05 | Month | 25 | Day |
Unpublished
No longer recruiting
2022 | Year | 02 | Month | 22 | Day |
2022 | Year | 03 | Month | 01 | Day |
2022 | Year | 08 | Month | 30 | Day |
2024 | Year | 01 | Month | 31 | Day |
2022 | Year | 05 | Month | 25 | Day |
2024 | Year | 10 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054563